Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174

被引:88
作者
Kaukonen, KM [1 ]
Olkkola, KT [1 ]
Neuvonen, PJ [1 ]
机构
[1] Univ Helsinki, Dept Clin Pharmacol, FIN-00290 Helsinki, Finland
关键词
fluconazole; losartan;
D O I
10.1007/s002280050405
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Losartan is metabolised to its active metabolite E-3174 by CYP2C9 and CYP3A4 in vitro. Itraconazole is an inhibitor of CYP3A4, whereas fluconazole affects CYP2C9 more than CYP3A4. We wanted to study the possible interaction of these antimycotics with losartan in healthy volunteers. Methods: A randomised, double-blind, three-phase crossover study design was used. Eleven healthy volunteers ingested orally, once a day for 4 days, either itraconazole 200 mg, fluconazole (400 mg on day 1 and 200 mg on days 2-4) or placebo (control). On day 4, a single 50-mg oral dose of losartan was ingested. Plasma concentrations of losartan, E-3174, itraconazole, hydroxy-itraconazole and fluconazole were determined over 24 h. The blood pressure and heart rate were also recorded over 24 h. Results. The mean peak plasma concentration (C-max) and area under the curve [AUC(0-infinity)] of E-3174 were significantly decreased by fluconazole to 30% and to 47% of their control values, respectively; and the t(1/2) was increased to 167%. Fluconazole caused only a nonsignificant increase (23-41%) in the AUC and tip of the unchanged losartan. Itraconazole had no significant effect on the pharmacokinetic variables of losartan or E-3174. The ratio AUC(0-infinity)(E-3174)/AUC (0-infinity)(losartan) was 60% smaller during the fluconazole than during the placebo and itraconazole phases. No clinically significant changes in the effects of losartan on blood pressure and heart rate were observed between fluconazole, itraconazole and placebo phases. Conclusion: Fluconazole but not itraconazole interacts with losartan by inhibiting its metabolism to the active metabolite E-3174. This implicates that, in man, CYP2C9 is a major enzyme for the formation of E-3174 from losartan. The clinical significance of the fluconazole-losartan interaction is unclear, but the possibility of a decreased therapeutic effect of losartan should be kept in mind.
引用
收藏
页码:445 / 449
页数:5
相关论文
共 16 条
  • [1] DETERMINATION OF ITRACONAZOLE IN SERUM WITH HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE DETECTION
    ALLENMARK, S
    EDEBO, A
    LINDGREN, K
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1990, 532 (01): : 203 - 206
  • [2] EFFECT OF FLUCONAZOLE ON THE DISPOSITION OF PHENYTOIN
    BLUM, RA
    WILTON, JH
    HILLIGOSS, DM
    GARDNER, MJ
    HENRY, EB
    HARRISON, NJ
    SCHENTAG, JJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (04) : 420 - 425
  • [3] SIMULTANEOUS DETERMINATION OF A NOVEL ANGIOTENSIN-II RECEPTOR BLOCKING-AGENT, LOSARTAN, AND ITS METABOLITE IN HUMAN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    FURTEK, CI
    LO, MW
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 573 (02): : 295 - 301
  • [4] HARGREAVES JA, 1994, BR J CLIN PHARM, V38, pP175
  • [5] ASSAY OF FLUCONAZOLE BY MEGABORE CAPILLARY GAS-LIQUID-CHROMATOGRAPHY WITH NITROGEN-SELECTIVE DETECTION
    HARRIS, SC
    WALLACE, JE
    FOULDS, G
    RINALDI, MG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) : 714 - 716
  • [6] Itraconazole greatly increases plasma concentrations and effects of felodipine
    Jalava, KM
    Olkkola, KT
    Neuvonen, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (04) : 410 - 415
  • [7] Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
    Lo, MW
    Goldberg, MR
    McCrea, JB
    Lu, H
    Furtek, CI
    Bjornsson, TD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (06) : 641 - 649
  • [8] DRUG CONCENTRATION RESPONSE RELATIONSHIPS IN NORMAL VOLUNTEERS AFTER ORAL-ADMINISTRATION OF LOSARTAN, AN ANGIOTENSIN-II RECEPTOR ANTAGONIST
    MUNAFO, A
    CHRISTEN, Y
    NUSSBERGER, J
    SHUM, LY
    BORLAND, RM
    LEE, RJ
    WAEBER, B
    BIOLLAZ, J
    BRUNNER, HR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (05) : 513 - 521
  • [9] MIDAZOLAM SHOULD BE AVOIDED IN PATIENTS RECEIVING THE SYSTEMIC ANTIMYCOTICS KETOCONAZOLE OR ITRACONAZOLE
    OLKKOLA, KT
    BACKMAN, JT
    NEUVONEN, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (05) : 481 - 485
  • [10] The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
    Olkkola, KT
    Ahonen, J
    Neuvonen, PJ
    [J]. ANESTHESIA AND ANALGESIA, 1996, 82 (03) : 511 - 516